In a study evaluating the effectiveness of treating MLK-1 xenograft tumors in a mouse xenograft model with Tazemetostat—an EZH2 inhibitor—for 50 days, showed a significant attenuation of tumor growth by day 19 of treatment; however, a complete cessation of tumor growth was not achieved [26]. The gene discussed is EZH2; the disease is neoplasm.